PTC Therapeutics Grants RSUs to New Hire, Strengthening Workforce and Commitment to Innovation

PTC Therapeutics Expands Workforce with Strategic RSU Grant for New Hire

PTC Therapeutics, Inc. announces the approval of 300 restricted stock units (RSUs) for a recently hired non-executive employee, effective January 2, 2026. This strategic grant, sanctioned by the company's Compensation Committee, is designed to incentivize the new employee's acceptance of the role within the organization. Each RSU provides the right to receive one share of common stock upon vesting, reflecting PTC’s commitment to attracting top talent in the biopharmaceutical sector. The vesting schedule spans four years, with 25% of the units vesting on each anniversary of the hire date, contingent on the employee's ongoing service at PTC.

This move aligns with PTC Therapeutics' broader strategy to foster a robust workforce capable of driving innovation in the development of therapies for rare disorders. By offering RSUs, PTC not only enhances its compensation package but also aligns employee interests with the long-term success of the company. As PTC Therapeutics continues to advance its diverse portfolio of transformative therapies, this grant exemplifies the company's dedication to building a team that is invested in its mission to address critical healthcare needs.

Furthermore, the RSU grant underscores PTC's adherence to Nasdaq Listing Rule 5635(c)(4), which governs the issuance of stock options and other equity awards. This regulatory compliance is crucial for maintaining investor confidence and ensuring that the company meets its obligations as a publicly traded entity. PTC's focus on aligning employee incentives with organizational goals reflects a strategic approach that is essential for sustaining its competitive edge in the biopharmaceutical industry.

In addition to enhancing its workforce, PTC Therapeutics remains committed to advancing its pipeline of innovative treatments. The company continues to leverage its scientific expertise and global infrastructure to provide access to vital therapies for patients with unmet medical needs. Interested parties can find more information about PTC Therapeutics through its official website and social media channels, reinforcing the company's dedication to transparency and stakeholder engagement. For inquiries, investors can reach out to Ellen Cavaleri, while media questions can be directed to Jeanine Clemente.